A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Elagolix (Primary) ; Estradiol/norethisterone (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors AbbVie
- 10 Oct 2018 Results of a subgroup analysis assessing eficacy and safety of elagolix in a subgroup of women with both UF and adenomyosis, presented at the American Society for Reproductive Medicine Scientific Congress 2018.
- 05 Oct 2018 Results published in the Obstetrics and Gynecology
- 23 May 2018 Results asessing effect of elagolox on quality of life presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.